Tariff whiplash is back in the picture this week, sending major indices lower. 

This time, the Trump administration is looking at the EU to make some deals. Trump back out flexing his tariff "muscles" again today is all the profit-takers needed to hear on a holiday Friday to hit the sell button.

We’ve seen this play out before. 

A strategic bet on companies with strong consumer demand and solid execution in the face of rising fear paid off handsomely for our Tariff Buy Alert Bonus Report. 

Now we see another area of opportunity emerging. 

Andy and Landon broke down the sector and 4 stocks we’re watching on this week’s Founders Call. 

Here’s an overview of the biggest news and largest movers in our portfolio in the last week through close on Thursday, May 22:

Infinite Hold Update 

Tesla (TSLA): Andy talked about TSLA in detail today on the Schwab Network. Watch below to see how we see things playing out in the next month ahead of the Robotaxi rollout in Austin.

Bitcoin: Bitcoin hit all-time highs earlier this week…or did it? Andy is diving into this concept as we speak. Members can expect a special report next week!

Amazon (AMZN): Bill Ackman confirmed a new stake in AMZN this week, calling the April dip a rare buying opportunity. His bet centers on retail margin improvement and long-term cash flow durability. Claude 3.5’s release brought fresh attention to AWS, where the model was trained using Amazon’s in-house Trainium chips. That launch helps validate Amazon’s plan to reduce reliance on Nvidia and monetize AI through infrastructure rather than apps. Bullish.

Portfolio Update

Tough week for some of the names in our portfolio alongside market pullback at large. We expect volatility when major announcements like this happen. We’re especially proud of two of our biggest winners (overall, and this week) – enjoy!

Oklo (OKLO): +30% (today)

Oklo is ripping higher today, up more than 30% while the broader market pulls back. The move comes ahead of an executive order signing by President Trump, expected this afternoon, that will fast-track nuclear reactor approvals and secure domestic fuel supply chains. Wedbush raised its price target to $55 this morning, citing Oklo's edge as one of the only advanced fission companies with a licensed design and near-term deployment roadmap.

Today’s move places our current OKLO gain over +106% in less than month. Incredible!

If you’ve played OKLO on its way up with us, send us over a note so we can celebrate. 

Robinhood (HOOD): +4%

Robinhood continues to exude strong growth from rising retail investing and a growing line of products and services. Members stay tuned – we have a Robinhood Deep Dive in the works that will go out next week. Data continues to look solid. 

SoundHound (SOUN): -14%

SoundHound shares are slipping this week as investors react to a looming May 27 deadline tied to a class action lawsuit over past accounting issues. The case focuses on delays and internal control problems related to its 2024 acquisitions. SoundHound builds voice AI systems used by restaurants, automakers, and smart device makers, allowing users to place orders or search using natural language. 

Web visits are up 73%, pointing to real traction even as legal overhang weighs on the share price. 

We remain bullish, with our position still firmly in the green and forward-looking digital traffic supporting continued growth.

Oscar Health (OSCR): -17%

OSCR shares slid this week in response to a Trump administration announcement that it would ramp up audits of insurance firms that offered Medicare Advantage. This move is expected to take back roughly $500 million per year from patient overpayments across health insurance firms. While OSCR is one of the firms that offer Medicare Advantage plans, the move is unlikely to create a drastic change to the company's bottom line. We are very early in this position and see this pullback as an accumulation opportunity, or nice entry if you have been sidelined but want to get in.

Hims&Hers (HIMS): -17%

Wall Street analysts expressed concerns over the company’s growth outlook due to out of pocket drug prices capping out and slowing sales. The FDA’s ban on compounded drugs with semaglutide, the active ingredient in popular weight-loss drugs like Ozempic, took effect this week. We aren’t surprised by near-term volatility, especially considering the stock’s recent run higher. HIMS consumer interest remains explosive and the company is continuing to provide value to consumers with unique partnerships and DTC health/wellness offerings. We will continue to monitor forward-looking demand for changes, but right now it remains robust.

Portfolio Spotlight: Reddit (RDDT)

We had a great question come in from a member this week: Is Reddit engagement dropping due to reliance on AI instead of the old google search with “reddit” trick?

On our end, the data is very telling…

Members Only Beyond This Point